Diabetes, Vol 43, Issue 3 430-432, Copyright © 1994 by American Diabetes Association

ARTICLES

Fibrinogen plasma levels as a marker of thrombin activation in diabetes

A Ceriello, C Taboga, R Giacomello, E Falleti, G De Stasio, E Motz, S Lizzio, F Gonano and E Bartoli
Department of Clinic and Experimental Pathology, University of Udine, Italy.

This study attempted to verify the existence of a correlation between fibrinogen, a major cardiovascular risk factor in diabetes, and indexes of thrombin generation and action, prothrombin fragment 1 + 2 (F1 + 2), and D-dimer (D-D), in a group of diabetic subjects compared with a matched control group. Forty insulin-dependent diabetes mellitus patients and 30 matched healthy control subjects participated in this study. The subjects were tested for the following parameters: fibrinogen, prothrombin F1 + 2, D-D, fasting glycemia, and HbA1c. In addition, 5 diabetic subjects who maintained stable fibrinogen plasma levels > 300 mg/dl for at least 6 months before the study were treated with 12,500 U/day subcutaneous heparin for 7 days. Diabetic subjects showed increased levels of fibrinogen, prothrombin F1 + 2, and D-D plasma levels. Simple linear regression analysis detected a positive correlation between fibrinogen and prothrombin F1 + 2, D-D, and glycosylated HbA1c. In the five diabetic subjects treated with heparin fibrinogen, prothrombin F1 + 2 and D-D levels decreased at the end of the treatment. All these parameters returned to baseline after 7 days of washout. These data indicate that fibrinogen plasma levels are correlated to parameters of thrombin activation in plasma in diabetic patients and suggest that high fibrinogen plasma levels might be a risk marker for cardiovascular disease in diabetes because it is an expression of an existing thrombophilia.
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				E. Vericel, C. Januel, M. Carreras, P. Moulin, and M. Lagarde Diabetic Patients Without Vascular Complications Display Enhanced Basal Platelet Activation and Decreased Antioxidant Status Diabetes, April 1, 2004; 53(4): 1046 - 1051. [Abstract] [Full Text] [PDF]

				M. E. Carr Jr, M. H. Hackney, S. J. Hines, S. P. Heddinger, S. L. Carr, and E. J. Martin Enhanced Platelet Force Development Despite Drug-Induced Inhibition of Platelet Aggregation in Patients with Thromboanglitis Obliterans: Two Case Reports Vascular and Endovascular Surgery, November 1, 2002; 36(6): 473 - 480. [Abstract] [PDF]

				A. Fu and K. S. Nair Age effect on fibrinogen and albumin synthesis in humans Am J Physiol Endocrinol Metab, December 1, 1998; 275(6): E1023 - E1030. [Abstract] [Full Text] [PDF]